Patent · US Active

Compositions and methods for modified dendrimer nanoparticle delivery

US10548959B2 · kind B2 · utility

1Cited by

1References

26Claims

0Family size

Assignees

Inventors

Omar Khan · Philadelphia, US
Jasdave S. Chahal · Arlington, US
Daniel Griffith Anderson · Framingham, US
Hidde L. Ploegh · Brookline, US
Robert S. Langer · Newton, US
Tyler E. Jacks · Newton, US
David A. Canner · Cambridge, US

Key dates

Filing date	Sep 23, 2016
Grant date	Feb 4, 2020
Priority date	—
Expiry date	Mar 7, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.